Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie's Gonzalez Calls Break-Up Proposal Rational, But Premature

Apr 27 2017

• By Joseph Haas

Related Content

Setback For AbbVie’s Humira As English Court Decision Clears Way For Biosimilars

Mar 08 2017

Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

Jan 27 2017

AbbVie’s Cancer Expansion Is Paying Off

Jan 27 2017

AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients

Apr 20 2017

Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy

Apr 20 2017

Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D

Sep 23 2016

Promise Of US Tax Reform Simmers, But On The Backburner

Apr 12 2017

Beyond Humira: How AbbVie Plans To Hold Its Immunology Leadership Reign

Jun 06 2016

Related Companies

AbbVie Inc.

Abbott

Pfizer Inc.

Amgen, Inc.

Boehringer Ingelheim GmbH

Pharmacyclics, Inc.

Additional Topics

Sales & Earnings Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window